Change in FeNO with dupilumab and tezepelumab in severe eosinophilic asthma

被引：0
|
作者：
Gates, J. [1 ]
Hearn, A. [1 ]
Maynard-Paquette, A. C. [1 ]
Green, L. [1 ]
Thomson, L. [1 ]
Fernandes, M. [1 ]
Roxas, C. [1 ]
Lam, J. [1 ]
d'Ancona, G. [1 ]
Dhariwal, J. [1 ]
Nanzer, A. M. [1 ]
Jackson, D. J. [1 ]
机构：
[1] Guys & St Thomas NHS Trust, Guys Severe Asthma Ctr, London, England
来源：
THORAX | 2023年 / 78卷 / SUPPL_4期
关键词：
D O I：
10.1136/thorax-2023-BTSabstracts.411
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M22
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [41] Tezepelumab in Adults and Adolescents with severe, uncontrolled Asthma
    不详
    ALLERGOLOGIE, 2021, 44 (08) : 577 - 578
  • [42] Tezepelumab in severe asthma: a profile of its use
    Yahiya Y. Syed
    Drugs & Therapy Perspectives, 2023, 39 : 393 - 403
  • [43] Severe Eosinophilic Asthma
    Bakakos, Agamemnon
    Loukides, Stelios
    Bakakos, Petros
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (09)
  • [44] Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
    Agache, Ioana
    Beltran, Jessica
    Akdis, Cezmi
    Akdis, Mubeccel
    Canelo-Aybar, Carlos
    Canonica, Giorgio Walter
    Casale, Thomas
    Chivato, Tomas
    Corren, Jonathan
    Del Giacco, Stefano
    Eiwegger, Thomas
    Firinu, Davide
    Gern, James E.
    Hamelmann, Eckard
    Hanania, Nicola
    Makela, Mika
    Martin, Irene Hernandez
    Nair, Parameswaran
    O'Mahony, Liam
    Papadopoulos, Nikolaos G.
    Papi, Alberto
    Park, Hae-Sim
    Perez de Llano, Luis
    Posso, Margarita
    Rocha, Claudio
    Quirce, Santiago
    Sastre, Joaquin
    Shamji, Mohamed
    Song, Yang
    Steiner, Corinna
    Schwarze, Jurgen
    Alonso-Coello, Pablo
    Palomares, Oscar
    Jutel, Marek
    ALLERGY, 2020, 75 (05) : 1023 - 1042
  • [45] Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
    Gawlewicz-Mroczka, Agnieszka
    Przybyszowski, Marek
    Bochenek, Grazyna
    Mroczka, Maria
    Sladek, Krzysztof
    RESPIRATORY MEDICINE CASE REPORTS, 2024, 52
  • [46] Cost-effectiveness of tezepelumab in Canada for severe asthma
    Habash, Mara
    Guiang, Hannah
    Mayers, Irvin
    Quinton, Anna
    Vuong, Vivian
    Dineen, Aidan
    Singh, Sumeet
    Gibson, Danny
    Turner, Adrian P.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 902 - 914
  • [47] INITIAL RESPONSES TO TEZEPELUMAB IN A COMPLEX SEVERE ASTHMA POPULATION
    Berrar-Torre, I
    Stead, R.
    Lawless, E.
    Statescu, I
    Campbell, E.
    Mamo, S.
    Brennan, V
    Patel, P. H.
    THORAX, 2023, 78 (SUPPL_4) : A184 - A184
  • [48] Correction to: Tezepelumab in severe asthma: a profile of its use
    Yahiya Y. Syed
    Drugs & Therapy Perspectives, 2024, 40 : 43 - 43
  • [49] Tezepelumab: patient selection and place in therapy in severe asthma
    Menzella, Francesco
    Munari, Sara
    Corsi, Lorenzo
    Tonin, Silvia
    Cestaro, Walter
    Ballarin, Andrea
    Floriani, Ariel
    Dartora, Cristina
    Senna, Gianenrico
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2024, 52 (04)
  • [50] The prevalence of severe asthma and severe eosinophilic asthma in Finland
    Viinanen, Arja
    Ilmarinen, Pinja
    Mehtala, Juha
    Ylisaukko-Oja, Tero
    Idanpaan-Heikkila, Juhana J.
    Kankaanranta, Hannu
    Lehtimaki, Lauri
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345